Furthermore, KRAS mutations co-occurring with TP53 mutations are associated with increased intratumoral T-cell infiltration, programmed cell death protein (PD-1) expression, and prolonged clinical benefit from anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) (41). This evidence concerns the gene TP53 and non-small cell lung carcinoma.